Acute pharmacogenetic dystonic reactions in a family with the CYP2D6 *41 allele: a case report

ConclusionsThe metabolism of ondansetron, metoclopramide, or prochlorperazine in patients with the *41CYP2D6 allele has not been studied. In this family, clinical evidence implicates the *41CYP2D6 allele as causing extrapyramidal adverse pharmacologic reactions. Patients with a family history of medication-induced dystonia involving these medications should be considered for pharmacogenomic testing, and patients carrying the *41CYP2D6 allele should consider reduction or avoidance of CYP2D6-mediated medications to minimize the potential risk of adverse extrapyramidal effects.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research